XML 27 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8
BUSINESS AGREEMENTS (Details) (USD $)
In Millions, unless otherwise specified
1 Months Ended
Sep. 30, 2013
Dong-A ST Co., Ltd.
License Agreements
Trius
Jun. 30, 2013
Amended and restated collaboration and license agreement with Hydra Biosciences, Inc.
Mar. 31, 2013
Astellas Pharma Inc.
License Agreements
Sep. 30, 2013
Bayer Pharma AG
Agreement for exclusive rights to commercialize tedizolid phosphate
Trius
Sep. 30, 2013
Bayer Pharma AG
Bayer
Agreement for exclusive rights to commercialize tedizolid phosphate
Trius
Licensing and Collaboration Agreements          
Remaining milestone payments $ 11.5        
Minimum period after the date of the first commercial sale over which royalties on annual net worldwide sales would be paid 12 years        
Upfront, non-refundable payment   15.0      
Payment for license agreement     25.0    
Payments made prior to acquisition         25.0
Percentage of future development costs of tedizolid required for global approval agreed to be reimbursed       25.00%  
Percentage of future development costs for local approval agreed to be reimbursed       100.00%  
Maximum payments to be received upon the achievement of certain development, regulatory, and commercial milestones       $ 69.1